Allan Levey on TBPB or Not to Be—The Latest on Muscarinic Receptor Agonists

COMMENT The paper by Jones et al. describes TBPB, a novel compound that represents a new generation of highly specific drugs. The study is important for the AD field because this drug will allow the role of the M1 muscarinic receptor in AD to be more clearly ...

Allan Levey on San Diego: Treating Forgetfulness—Triple Transgenics Provoke

COMMENT I concur with the other comments: The in-vivo M1 agonist treatment effect on Aß is very encouraging. It has long been clear that different muscarinic receptor subtypes have opposing actions on amyloidogenesis and other physiological processes, and that ...

Current Filters

TYPE: Comment x
Commentator: Levey, Allan x

Remove all filters

SEARCH RESULTS

Allan Levey on TBPB or Not to Be—The Latest on Muscarinic Receptor Agonists

Allan Levey on San Diego: Treating Forgetfulness—Triple Transgenics Provoke

Current Filters

Filter By